CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Communication Toolother
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Female gender
  • ✓Age 75-79 or ≥80
  • ✓History of stage 0-II breast cancer
  • ✓At least one Charlson comorbidity (diabetes, liver disease, prior/active malignancy other than non-melanoma skin cancer, HIV/AIDS, chronic kidney disease, prior MI/CHF, chronic lung disease, peripheral vascular disease, cerebrovascular disease, dementia, hemiplegia/paralysis, or connective tissue disorder)
Key exclusion· 2
  • ✕Unable to consent
  • ✕Does not read and write English

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03865654
NCT03865654N/ACompleted
CompareCT.gov

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Dana-Farber Cancer Institute·interventional·Posted Mar 7, 2019·Updated Aug 24, 2022

In Brief

A clinical study evaluating Communication Tool for Breast Cancer. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This research is being conducted to develop consensus on surveillance mammography and follow-up for breast cancer survivors who are age ≥75.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 7, 2019
Enrollment StartMay 16, 2019
Primary CompletionJul 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.3 years ago

Interventions

Communication Toolother

Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors